Plaintiffs Submit Proposal on Master Pleadings in Zofran (ondansetron) MDL

In March 2016, with more than 200 lawsuits pending in the Zofran (ondansetron) federal multi-district litigation (“MDL”) in the District of Massachusetts, plaintiffs submitted their proposal on the sequence and effect of “Master Pleadings.” In a sequence of master pleadings, usually created for administrative reasons, master complaints collate claims brought in each case into a single document outlining the reasons families have filed lawsuits. Master answers are then filed by defendants, responding to the allegations. In the Zofran (ondansetron) MDL, plaintiffs intend to file their master complaint against the anti-nausea drug’s manufacturer, GlaxoSmithKline LLC (“GSK”), no later than April 14, 2016, while GSK will file its answer by May 17, 2016.

Serving as co-lead on the Plaintiffs’ Executive Committee, Grant & Eisenhofer Director Beth Graham represents plaintiffs arguing that GSK illegally promoted the drug “off-label” for pregnancy-related nausea, claiming the drug caused children to be born with congenital heart defects, cleft palate, and other malformations. If you or a loved one took Zofran (ondansetron) during your first trimester and your child was born with a congenital heart defect or cleft palate, please call us today at 877-978-0169 for a confidential evaluation of your potential claim.

Real Time Analytics